NASDAQ:GYRE Gyre Therapeutics Q4 2025 Earnings Results & Report $4.74 +0.44 (+10.09%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Gyre Therapeutics missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 12, 2026. The company reported EPS of $0.04 versus the $0.08 consensus estimate, while revenue of $37.20 million topped the $36.30 million estimate by $892.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market Opens Gyre Therapeutics EPS ResultsActual EPS$0.04Consensus EPS $0.08Beat/MissMissed by -$0.04One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersGyre Therapeutics Revenue ResultsActual Revenue$37.20 millionExpected Revenue$36.30 millionBeat/MissBeat by +$892.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Gyre Therapeutics Q4 2025 Earnings FAQ Did Gyre Therapeutics beat earnings estimates for Q4 2025? Gyre Therapeutics (NASDAQ:GYRE) reported earnings of $0.04 per share for Q4 2025, missing the consensus estimate of $0.08. The report was announced on Thursday, March 12, 2026. What was Gyre Therapeutics' revenue for Q4 2025? Gyre Therapeutics reported revenue of $37.20 million for Q4 2025, against a consensus estimate of $36.30 million. Gyre Therapeutics Earnings HeadlinesGyre Therapeutics (NASDAQ:GYRE) Shares Climb 14.5% After Strong EarningsNovember 8, 2026 | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Stock Rating Raised to "Hold" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.November 16 at 1:00 AM | Profits Run (Ad)Gyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMGyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesNovember 5, 2026 | globenewswire.comGyre Therapeutics, Inc. enters into new employment agreements on October 16, 2026October 22, 2026 | msn.comSee More Gyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email. Email Address About Gyre TherapeuticsGyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure. The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.View Gyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need?Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.